Document is current
Any future updates will be listed below
-
Authors
Ritchie, Leona A.
Penson, Peter E.
Akpan, Asangaedem
Lip, Gregory Y. H.
Lane, Deirdre A.
- License Information
-
More Information
Article History
Received: 21 June 2023
Accepted: 28 November 2023
First Online: 16 January 2024
Declarations
:
: The study received sponsorship from the University of Liverpool (ref: UoL001537) on 05/05/2020. Ethical approval was obtained from Health and Care Research Wales (08/06/2020) and the Health Research Authority (15/06/2020) after favourable review by Wales Research Ethics Committee 4 (ref: 20/WA/0164). Informed consent was obtained following International Conference on Harmonisation Good Clinical Practice and Health Research Authority guidance. Adults with capacity were provided with a participant information sheet (PIS) and given as much time as they need to read over the information before obtaining written consent. Information provided within the PIS to covered the scenario of loss of capacity during the research. For adults without capacity, the LPA of Health and Welfare was provided with a consultee information sheet (CIS) and given as much time as they need to read over the information before obtaining a Consultee Declaration form. Information provided within the CIS to cover the scenario of regaining capacity during the research. Information sheets and consent/declaration forms sent via post if necessary due to COVID-19.
: Obtained on enrolment into research study. Information provided within the PIS and CIS explained that study results would be published in a scientific journal, but participants would not be identifiable from the published results.
: PEP owns four shares in AstraZeneca PLC and has received honoraria and/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Napp, Sanofi. GYHL has been a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Anthos and Daiichi-Sankyo, no fees are received personally. GYHL is co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899871. DAL has received investigator-initiated educational grants from Bristol-Myers Squibb (BMS), has been a speaker for Bayer, Boehringer Ingelheim, and BMS/Pfizer and has consulted for BMS, and Boehringer Ingelheim; LAR and AA have no competing interests to report.
